Cohance Lifesciences Invests Heavily in Capabilities in India and U.S.
The strategic investments by the CRDMO, which are aligned with its long-term strategy, will strengthen its integrated oligonucleotide platform and capabilities to delivery ADC solutions.
Innovator-focused global contract research, development, and manufacturing organization (CRDMO), Cohance Lifesciences, has announced that it is investing INR 230 million into its new current good manufacturing practice (CGMP) oligonucleotide building block manufacturing facility in Hyderabad, India (1). With this investment, the company will be able to take the high-value chemistries in modified nucleosides and locked nucleic acids (LNA) from laboratory scale to full commercial manufacturing.
The company will integrate this new facility with its pilot plant, used for early-stage synthesis, and will add fit-for-purpose GMP capacity of up to 700 kg per year. Additionally, the company has specified that there will be room available at the facility for future expansion.
“Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity,” said Vivek Sharma, Executive Chairman, Cohance Lifesciences, in a company press release (1). “This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics.”
This expanded capacity and broadened scale, in combination with advanced environmental controls, including ISP Class 8 cleanrooms and relative humidity (RH) controlled areas, align with the requirements of complex oligonucleotide building block production. Further, the company is progressing with the necessary validations and audits, and customer engagements are already underway.
In addition to its investment in Hyderabad, the company has also made a significant investment into bioconjugation capabilities in the U.S. According to an Aug. 12, 2025 press release, the company is putting USD 10 million into expanding its CGMP bioconjugation suite at its U.S. based subsidiary, NJ Bio, in Princeton, N.J., U.S. (2).
With the expanded capabilities, the company will strengthen its capabilities to deliver fully integrated antibody-drug conjugate (ADC) solutions from early-phase payload-linker synthesis through to complete ADC manufacturing for clinical supply.
“This investment marks a pivotal milestone in strengthening our footprint in the rapidly growing ADC space,” Sharma commented in the company press release (2). “By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster. As a global CRDMO, we’re excited to leverage our strong presence in both the U.S. and India to deliver differentiated value to innovators worldwide.”
References
Cohance. Cohance Lifesciences Announces INR 230 Million Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India. Press Release, Aug. 12, 2025.
Cohance. Cohance Lifesciences Announces USD 10 Mn Investment in cGMP Bioconjugation Suite at NJ Bio, Princeton, NJ, U.S. to Accelerate ADC Innovation. Press Release, Aug. 12, 2025.